Webinar: Preapproval Risk Mitigation Strategies & Proactive Safety Considerations

To be best prepared for postapproval safety monitoring, evaluation, and mitigation, biopharmaceutical companies must know what is required in terms of an RMP and a REMS. Preparation of these tools must begin during drug development. Postapproval safety is not just a postapproval consideration. The earlier in clinical development identified and potential risks are determined, the greater the opportunity there is to develop, evaluate, and start implementing a flexible and effective risk management strategy.

Discover ways biopharmaceutical companies can proactively prepare during drug development to monitor and assess patient safety in the postapproval period.

Webinar release date: December 2013

Contact us to discuss the latest preapproval risk mitigation strategies.